
IRON Stock Forecast & Price Target
IRON Analyst Ratings
Bulls say
Disc Medicine Inc. has strengthened its outlook for bitopertin, raising the probability of FDA approval to 100% from 75%, which may significantly enhance its market entry potential and revenue streams. The company's projections for near to medium-term sales demonstrate robust growth potential, with estimated revenues of $35 million in 2026, escalating to $615 million by 2029, driven by favorable adjustments in launch expectations. Additionally, the acquisition of a Commissioner’s National Priority Voucher (CNPV) for bitopertin is likely to expedite the drug application review process, further bolstering the company's value proposition in the competitive biopharmaceutical landscape.
Bears say
Disc Medicine Inc faces significant challenges that contribute to a negative outlook on its stock. The company is exposed to intellectual property risks that could lead to increased competition and the need for additional financing, posing threats to its revenue generation and overall valuation. Furthermore, there are concerns regarding the clinical efficacy and safety of its product candidates, particularly in the context of regulatory approvals, which could hamper the successful commercialization of its drug pipeline.
This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.
IRON Analyst Forecast & Price Prediction
Start investing in IRON
Order type
Buy in
Order amount
Est. shares
0 shares